Advertisement

Nicergolin

  • H. Herrschaft
Chapter

Zusammenfassung

Auf der Suche nach einem Ergot-Alkaloid mit ausgeprägt blockierender Wirkung auf alpha-adrenerge Rezeptoren wurde in den 60er Jahren das halbsynthetische Ergolinderivat Nicergolin entwickelt. Dem damaligen Verständnis der Ätiologie dementieller Erkrankungen folgend, konzentrierten sich pharmakologische Untersuchungen auf vasodilatatorische Effekte, die aus der alpha-1rezeptorblockierenden Wirkung der Substanz resultieren: Neben zahlreichen tierexperimentellen Studien (Le Poncin-Lafitte et al. 1984) wiesen auch Untersuchungen am Menschen eine Verbesserung der durchschnittlichen zerebralen Hemisphären-Durchblutung nach (Iliff et al. 1979). Weitere Untersuchungen offenbarten jedoch pharmakologische Effekte, welche als die eigentlichen Hauptwirkungen der Substanz angesehen werden und unabhängig von der ebenfalls bewirkten Zunahme der zerebralen Durchblutung sind; sie sind auch unter den Bedingungen der Hyperkapnie und somit maximalen Gefäßdilatation nachweisbar (Boismare und Lorenzo 1975).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aliprandi G v, Tantalo V (1979) Physiopathologie des Innenohres und Therapie der Perzeptionstaubheit. Arzneimittelforschung/Drug Res 29: 1287–1295Google Scholar
  2. Arcamone F, Glässer AG, Grafnetterova J, Minghetti A, Nicolella V (1972) Studies on the metabolism of ergoline derivatives. Metabolism of nicergoline in man and in animals. Biochem Pharmacol 21: 2205–2213PubMedCrossRefGoogle Scholar
  3. Arnold JD (1977) Unveröffentlichte Archivdaten (Farmitalia, Freiburg, Deutschland)Google Scholar
  4. Arrigo A, Moglia A, Borsotti L, Massarini M, Alfonsi E, Battaglia A, Saccetti GA (1982) Double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia. Int J Clin Pharm Res [Suppl 1] 2: 33–41Google Scholar
  5. Battaglia A, Bruni G, Ardia A, Sacchetti G (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebocontrolled study. Jags 37: 295–302Google Scholar
  6. Battaglia A, Annonik G, Pamparana F et al. (1995) Nicergoline in the long-term treatment of mild or moderate senile dementia. ECNP Congress, Venice, p 383Google Scholar
  7. Benzi G, De Bernardi M, Manzo L, Ferrara A, Pancheri P, Arrigoni E, Berte F (1972) Effect of lysergide and nicergoline on glucose metabolism investigated on the dog brain isolated in situ. J Pharm Sci 61, N 3: 348–352PubMedCrossRefGoogle Scholar
  8. Benzi G, Arrigoni E, Pastoris O, Villa RF, Dagani F, Marzatico F, Agnoli A (1979) Effect of some drugs on cerebral energy state during and after hypoxia and complete or incomplete ischemia. Biochem Pharmacol 28: 435–439PubMedCrossRefGoogle Scholar
  9. Beyer HH (1980) Die Verwendung von Nicergolin (Sermion®) bei Tinnitus aurium. Therapiewoche 30: 935–938Google Scholar
  10. Bianchine JR (1983) Unveröffentlichte Archivdaten (Farmitalia, Freiburg, Deutschland)Google Scholar
  11. Boismare F, Lorenzo J (1975) Study of the protection afforded by nicergoline against the effects of cerebral ischemia in the cat. Arzneimittelforschung/Drug Res 25: 410–413Google Scholar
  12. Bolli R, Ware JA, Brandon TA, Weilbaecher DG, Mace ML (1984) Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alphaadrenergic antagonist. J Am Coll Cardiol 3: 1417–1426PubMedCrossRefGoogle Scholar
  13. Borromei A (1989) Adjuvant therapy for Parkinson’s disease. Preliminary data of a multicentre study with nicergoline. Funct Neurol 4: 63–67Google Scholar
  14. Cattabeni F (1996) Protein kinase C in synaptic plasticity: a molecular traget in the treatment of congnitive disorders. 4th Int Nice/Springfield Symposium, NiceGoogle Scholar
  15. Chandra P, Paul A (1985) The effects of nicergoline and other vaso-active substances on molecular biological processes in the brain and their effects on the learning abilities of rats. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 119–130Google Scholar
  16. De Agopian P, Rosa A, Gautier JC, Lhermitte F (1973) Thromboses arteriélles expêrimentales. Effect d’un alpha-bloquant: la nicergoline. Nouv Presse Med 2: 2521–2524Google Scholar
  17. Dolce G, Zamponi A, Cecconi V, Pola P (1984) Clinicical and EEG assessment of neurodynamic effect of nicergoline in cerebral functions recovery after brain hemisphere lesions. Proceedings, 14th C.I.N.P. Congress, Florence, June 23Google Scholar
  18. Dolce G, Cecconi V, Zamponi A, Zylbergmann R, Maggi L, Battaglia A (1985) Terapia farmacologica associata a riabilitazione neuromotoria nel paziente: un nuovo approccio metodologica per la valutazione clinica di farmaci nootropi. Giorn Geront [Suppl] 62: 55–63Google Scholar
  19. Domzat T, Tutaj A, Zydecka B (1989) Nicergoline in the treatment of ischaemic cerebral stroke. Funct Neurol 4: 131–133Google Scholar
  20. Ehrly AM, Lardgraf H (1985) Einfluß von Nicergolin auf die Filtrabilität hyperosmolaren Blutes. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen: Fortschritte in der klinischen und experimentellen Nicergolin-Forschung. Springer, Berlin Heidelberg New York Tokyo, S 189 ffGoogle Scholar
  21. Fabbrini G, Martucci N, Battaglia A, Novellini R (1989) Nicergoline as a possible dopaminergic agent. Effects of serum prolactin levels. XIVth World Congress on Neurology, New Delhi, October 1989Google Scholar
  22. Fariello RG, Carfagna N (1991) Biological basis for synergism between pharmacological and behavioural intervention in the aging brain. Geriatria y Gerontologia 26 [Suppl 1]: 33Google Scholar
  23. Farmitalia Carlo Erba (1984) Plasma and brain levels of nicergoline and its metabolites in the rat. Confidential report 67l4/818i, June 1984Google Scholar
  24. Farmitalia Carlo Erba (1988) Comparative study of the bioavailability of three oral preparations of nicergoline in healthy volunteers. Confidential report 67l4/649iGoogle Scholar
  25. Fujihara M, Hirakoso K, Takahashi M, Nakamura T, Harigaya S (1986 a) Biological fate of nicergoline (3). Placental transfer and mammary excretion. Oyo Yakuri (Pharmacometrics) 32: 49–56Google Scholar
  26. Fujihara M, Hirakoso K, Takahashi M, Nakamura T, Harigaya S (1986 b) Biological fate of nicergoline (2). Biological fate in rats and dogs after oral administration. Oyo Yakuri (Pharmacometrics) 32: 31–48Google Scholar
  27. Granata M, Dondero D, Tomasinelli R (1984) Studio clinico controllato della nicergolina dell’insufficienza cerebrale senile. Atti Accad Med Lomb 39: 33–40Google Scholar
  28. Greiner GF (1980) Therapeutische Wirkung von Nicergolin (Sermion®) im HNO-Bereich. Therapiewoche 30: 348–351Google Scholar
  29. Gruppo Cooperativo Italiano per lo Studio Della Nicergolina (1985) Attivita della nicergolina nel deterioramento cerebrale senile: ricerche cliniche controlatte verso placebo. Giorn Geront [Suppl] 62: 27–43Google Scholar
  30. Heitz C, Descombesj J, Miller RC, Steclet JC (1986) Alpha-adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 123: 279–285PubMedCrossRefGoogle Scholar
  31. Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of niceroline in patients with multi-infarct dementia. Dementia 8: 9–17Google Scholar
  32. Italian Cooperative Study Group (1985) Attivita della nicergolina nel deterioramento cerebrale senile. Giorn Geront 62: 27–43Google Scholar
  33. Iliff LD, Du Boulay GH, Marshall JR, Ross RW, Symon L (1979) Wirkung von Nicergolin auf die Gehirndurchblutung. Arzneimittelforschung/Drug Res 29: 1277–1278Google Scholar
  34. Jori MC, De Paolis C, Battaglia A, Ardia A, Praga C (1985) Studio controllato multinazionale: nicergolina nel trattamento sintomatologico dell’invecchiamento cerebrale patologico. Giorn Geront 33: 1185Google Scholar
  35. Kohlenberg-Müller K, Meier GH, Kunz K, Wauschkuhn CH, Schaffler K (1991) Vergleichende Untersuchungen zur Bioverfügbarkeit von Nicergolin aus zwei unterschiedlichen Darreichungsformen im Steady State. Arzneimittelforschung/Drug Res 41: 28 ffGoogle Scholar
  36. Kugler J (1988) Electroencephalographic and psychometric measurements during treatment of cerebral insufficiency with nicergoline and co-dergocrine mesylate. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on nicergoline. Proceedings International Symposium, Rome, October 1987. Excerpta Medica, pp 68–76Google Scholar
  37. Kuzuya F, Hayakawa M (1985) Einfluß von Nicergolin auf die Thrombozytenaggregation und Erythrozytenverformbarkeit. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen: Fortschritte in der klinischen und experimentellen Nicergolin-Forschung. Springer, Berlin Heidelberg New York Tokyo, S 193Google Scholar
  38. Lagarde M, Guichardant M, Ghazi I, Dechavanne M (1980) Nicergoline, an anti-aggregating agent which inhibits release of arachidonic acid from human platelet phospholipids. Prostaglandins 19: 551–557PubMedGoogle Scholar
  39. Latkowsky B et al. (1987) Experience with Sermion® in the treatment of some inner ear diseases. Symposium Polish Neurological Society (Section of Therapy), Warsaw, March 27 (Abstracts, pp 72)Google Scholar
  40. Le Poncin-Lafitte M, Grosdemouge C, Billon C, Rapin JR (1981) Nicergoline: deoxyglucose uptake and cerebral blood flow under hypoxia. In: Les alpha-bloquants, pharmacologie experimentale et clinique. Masson, Paris, pp 321–325Google Scholar
  41. Le Poncin-Lafitte M, Grosdemouge C, Duterte D, Rapin JR (1984) Simultaneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline. Gerontology 30: 109–119PubMedCrossRefGoogle Scholar
  42. Maiolo AT, Bianchi Porro G, Galli C, Sessma M (1972) Effects de la nicergoline sur l’hémodynamique cérébrale et la metabolisme cérébral dans l’hypertension artérielle essentielle et l’arteriosclerose. Clin Thér 62: 239–252Google Scholar
  43. Martucci N, Battaglia A (1989) A review of italian studies with Nicergoline in the aging brain. Funct Neurol 4: 27–32Google Scholar
  44. Martucci N, Manna V, Battaglia A (1985) Eine placebokontrollierte Studie mit Nicergolin an Patienten mit organischem Hirnsyndrom, die an kochleären und vestibulären Störungen leiden. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin Heidelberg New York Tokyo, S 57–66Google Scholar
  45. McArthur RA, Cervini MA, Carfagna N (1993) Nicergoline reverses the learning deficits in the radial maze of aged rats. Br Assoc Psychopharmacol, CambridgeGoogle Scholar
  46. Megna C, Calabrese S, Monitillo V, Craca A, Del Prete M (1989) Nootropic and psychotropic drugs in hemiplegic patients during rehabilitation. Funct Neurol 4: 143–147Google Scholar
  47. Moglia A, Arrigo A (1989) Ergot derivatives in the aging brain correlation between EEG spectral analysis and clinical findings. Funct Neurol 4: 23–26Google Scholar
  48. Moglia A, Arrigo A, Battaglia A, Sacchetti G (1985) Correlation between computerized EEG and clinical findings in patients with senile dementia. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 45–50Google Scholar
  49. Moretti A, Arcari G, Pegrassi L (1979) übersicht über pharmakologische Studien mit Nicergolin. Arzneimittelforschung/Drug Res 29(II), 8aGoogle Scholar
  50. Moretti A, Carfagna N, Caccia C, Carpentieri M, Amico A, Marchi G, Trunzo F (1985) Neurochemical effects of ergoline derivatives. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 103–110Google Scholar
  51. Moretti A, Carfagna N, Caccia C, Carpentieri M (1988) Effects of ergolines on neurotransmitter systems in the rat brain. Arch Int Pharmacodyn 294: 33–45PubMedGoogle Scholar
  52. Nicergoline Cooperative Study Group (1990) A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr Ther Res 48: 597–612Google Scholar
  53. Pasqui AL, Mancini A (1984) Relazione sull’attivita e tollerabilita della nicergolina dell’insufficienza cerebrale senile: confronte con placebo secondo un disegno crossover. Relazione per Ministero di SanitaGoogle Scholar
  54. Paul A, Chandra P (1979) Einfluß von Nicergolin auf molekularbiologische Prozesse im Gehirn und seine Auswirkung auf die Lernfähigkeit der Ratte. (Effect of nicergoline on molecular biological processes in the brain and its effect on the learning ability of the rat.) Arzneimittelforschung/Drug Res 29: 1238–1251Google Scholar
  55. Pogliani E, Delia Volpe A, Ferrari R, Recalcati P, Praga C (1975) Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study. Il Farmaco (Prat) 30: 630–640Google Scholar
  56. Post C (1995) Pharmacological basis for the clinical effects of nicergoline in dementia. First European Congress of Pharmacology, MilanGoogle Scholar
  57. Praga C, Tantalo V, Maragoni R (1979) Nicergolin und Thrombocytenaggregation. Drug Res 29: 1270–1276Google Scholar
  58. Rafelson ME, Migne J, Santonja R, Derouette JC, Robert L (1980) Effect of an alpha-blocking agent, nicergoline, on the interaction between blood platelets, elastin and endothelial cells. Biochem Pharmacol 29: 943–947PubMedCrossRefGoogle Scholar
  59. Renon P, Le Mouel C (1990) Injizierbares Nicergolin bei der Behandlung cochlearer Notfälle. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin Heidelberg New York Tokyo, S 207–215Google Scholar
  60. Rossi AC, Carfagna N, Caccia C, Carpentieri M, Moretti A (1988) Neurochemical effects of ergoline derivatives. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain an update on nicergoline. Proceedings International Symposium, Rome, October 1987. Excerpta Medica, pp 16–24Google Scholar
  61. Rossi A, Battaglia A, Novellini R, Buonamici M, Carfagna N, Orlando N, Pamparana F (1990) Nicergoline: pharmacological properties and clinical studies in aging brain. In: Alan R (ed) Aging brain and dementia: new trends in diagnosis and therapy. Liss, New York, pp 549–576Google Scholar
  62. Rubegni M, Provvedi D (1984) Nicergoline nell’ insufficienza cerebrale senile. Risultati di due studi clinici controllati verso placebo. Relazione per Ministero di SanitaGoogle Scholar
  63. Saletu B (1991) Codergocrinetype drugs in the pharmacotherapyof mental and cognitive disorders in aging. Proceedings, 5th World Congress of Biological Psychiatry, Florence, June, 9–14, 1991 (Excerpta Medica International Congress Series)Google Scholar
  64. Saletu B, Grünberger J, Linzmayer L, Anderer P (1990a) Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm [P-D Sect] 2: 305–325CrossRefGoogle Scholar
  65. Saletu B, Anderer P, Grünberger J (1990b) Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 11: 1–22PubMedCrossRefGoogle Scholar
  66. Saletu B, Paulus E, Linzmayer L et al. (1995) Nicergoline in senile dementia of Alzheimer type and multiinfarct dementia: a double blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385–395PubMedCrossRefGoogle Scholar
  67. Shintomi K, Egon H, Tanaka T, Itakura T, Yoshimoto K, Matsamoto M, Matsuoka Y (1986) Pharmacological study of nicergoline (I). Protective effect against anoxic brain damages in animals. Folia Pharmacol Jpn 87: 445–456CrossRefGoogle Scholar
  68. Shintomi K, Yoshimoto K, Ogawa Y, Itakura T, Ikezawa K, Narita H, Ishizuka T, Yamaguchi I, Yamada K (1987) Pharmacological effects of nicergoline and its metabolites, decomposition products and impurities in animals. J Pharmacobiodyn 10: 35–48PubMedCrossRefGoogle Scholar
  69. Split W et al. (1987) Treatment of insufficiency of the vertebro-basilar arterial system with Sermion® (Nicergolin). Symposium, Polish Neurological Society (Section of Therapy), Warsaw, March 27 (Abstracts, p 53)Google Scholar
  70. Turchiaro GG, Scornaienghi D (1984) Impiego della nicergolina nel trattamento dell’insufficienza cerebrale senile. Studio clinico controllato verso placebo. Relazione per Ministero di SanitaGoogle Scholar
  71. Voronina TA, Nerobkova LN, Garibova TL, Divkova M, Nikolov R, Nikolova M, Markina NV (1988) Effect of nicergoline on learning and memory. Meth Find Exp Clin Pharmacol 10: 431–435Google Scholar
  72. Zappoli R, Versari A, Paganini M, Arnetoli G, Battaglia A, Ardia A, Maniero A (1988) Effect of long-term nicergoline treatment on contingent negative variation activity and clinical status of patients with presenile idiopathic mental deterioration: preliminary findings. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on nicergoline. Proceedings, International Symposium, Rome, October 1987. Excerpta Medica, pp 72–83Google Scholar
  73. Zylberman MR, Fontana M, Dolce G (1988) Effects of Nicergoline on learning, mood and behaviour in hemiplegic patients undergoing rehabilitation. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on Nicergoline. Proceedings, International symposium. Rome, October 1987. Excerpta Medica, pp 57–63Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H. Herrschaft

There are no affiliations available

Personalised recommendations